Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.
Ishikawa T, Kokura S, Enoki T, Sakamoto N, Okayama T, Ideno M, Mineno J, Uno K, Yoshida N, Kamada K, Katada K, Uchiyama K, Handa O, Takagi T, Konishi H, Yagi N, Naito Y, Itoh Y, Yoshikawa T. Ishikawa T, et al. PLoS One. 2014 Jan 31;9(1):e83786. doi: 10.1371/journal.pone.0083786. eCollection 2014. PLoS One. 2014. PMID: 24497917 Free PMC article. Clinical Trial.
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
Uchiyama K, Takagi T, Iwamoto Y, Kondo N, Okayama T, Yoshida N, Kamada K, Katada K, Handa O, Ishikawa T, Yasuda H, Sakagami J, Konishi H, Yagi N, Naito Y, Itoh Y. Uchiyama K, et al. Among authors: ishikawa t. PLoS One. 2014 Apr 24;9(4):e95080. doi: 10.1371/journal.pone.0095080. eCollection 2014. PLoS One. 2014. PMID: 24762746 Free PMC article.
Cytotoxic T lymphocyte-associated antigen 4 inhibition increases the antitumor activity of adoptive T-cell therapy when carried out with naïve rather than differentiated T cells.
Ishikawa T, Adachi S, Okayama T, Kokura S, Mizushima K, Doi T, Matsuyama T, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Naito Y, Itoh Y, Yoshikawa T. Ishikawa T, et al. Oncol Rep. 2015 May;33(5):2545-52. doi: 10.3892/or.2015.3815. Epub 2015 Feb 24. Oncol Rep. 2015. PMID: 25738564
Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T, Ishikawa T, Sugatani K, Yoshida N, Kokura S, Matsuda K, Tsukamoto S, Ihara N, Kuriu Y, Nakanishi M, Nakamura T, Kamada K, Katada K, Uchiyama K, Takagi T, Handa O, Konishi H, Yagi N, Naito Y, Otsuji E, Hosoi H, Miki T, Itoh Y. Okayama T, et al. Among authors: ishikawa t. Clin Ther. 2015 Jun 1;37(6):1259-69. doi: 10.1016/j.clinthera.2015.03.012. Epub 2015 Apr 7. Clin Ther. 2015. PMID: 25862137
Tumor inoculation site affects the development of cancer cachexia and muscle wasting.
Matsuyama T, Ishikawa T, Okayama T, Oka K, Adachi S, Mizushima K, Kimura R, Okajima M, Sakai H, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Kokura S, Naito Y, Itoh Y. Matsuyama T, et al. Among authors: ishikawa t. Int J Cancer. 2015 Dec 1;137(11):2558-65. doi: 10.1002/ijc.29620. Epub 2015 Jun 10. Int J Cancer. 2015. PMID: 26016447
7,845 results